Results 11 to 20 of about 92,873 (239)

Isocitrate Dehydrogenase-Mutant Astrocytomas: Risk Stratification and Therapeutic Advance. [PDF]

MedComm (2020)
This graphical abstract synthesizes the core logic of our revised review by linking integrated diagnosis, risk stratification, and trajectory‐based management in IDH‐mutant astrocytomas across CNS WHO Grades 2–4. It highlights lineage‐defining molecular classification (IDH mutation with core co‐alterations), integrated histomolecular grading, and key ...
Wei S, Xu X, Bao J, Pan Z.
europepmc   +2 more sources

Severe and prolonged myelosuppression during concomitant temozolomide and radiotherapy treatment in a patient with glioblastoma multiforme [PDF]

, 2015
Aims: We describe the case of a patient with glioblastoma (GBM) who developed severe and prolonged myelosuppression during concomitant daily temozolomide (TMZ) and radiotherapy (RT) treatment.
ALOE SPIRITI, Maria Antonietta, Carnevale, Alessia, Cox, Maria, DE SANCTIS, Vitaliana, Gentile, Giovanna, MAURIZI ENRICI, Riccardo, Minniti, Giuseppe, Porrini, ì Raffaele, Ruco, Luigi, Scaringi, Claudia, Simmaco, Maurizio, Tafuri, Agostino, Valeriani, Maurizio   +12 more
core   +1 more source

Neoadjuvant chemotherapy with capecitabine and temozolomide for unresectable pancreatic neuroendocrine tumor. [PDF]

, 2012
Pancreatic neuroendocrine tumors (PNETs) are relatively rare tumors that arise in the endocrine cells of the pancreas. Historically, somatostatin analogues have been used in this disease primarily for symptom control and, to a limited extent, disease ...
Devata, Sumana, Kim, Edward J
core   +2 more sources

Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development

Frontiers in Pharmacology, 2022
Glioblastoma multiform is the most aggressive primary type of brain tumor, representing 54% of all gliomas. The average life span for glioblastoma multiform is around 14–15 months instead of treatment.
Priya Bisht, V. Udaya Kumar, Ruchi Pandey, Ravichandiran Velayutham, Nitesh Kumar   +4 more
doaj   +1 more source

The potential role and application of PARP inhibitors in cancer treatment [PDF]

, 2009
Background: Since many anti-cancer agents act by inflicting DNA damage on tumour cells, there is increasing interest in the use of inhibitors of DNA repair to increase the cytotoxicity of these agents.
Chalmers, Anthony J
core   +2 more sources

Alternative temozolomide dosing regimens and novel combinations for the treatment of advanced metastatic melanoma

Oncology Reviews, 2011
Over the past 30 years, there has been no significant improvement in treatment outcomes for patients with advanced stage IV metastatic melanoma, and prognosis remains poor.
Wen-Jen Hwu, Ana E. Ayala, Ingrid M. Hernandez   +2 more
doaj   +1 more source

Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide

Frontiers in Oncology, 2020
Glioblastoma, the most common primary central nervous system tumor, is characterized by extensive vascular neoformation and an area of necrosis generated by rapid proliferation.
Monserrat Llaguno-Munive, Monserrat Llaguno-Munive, Sebastián León-Zetina, Inés Vazquez-Lopez, María del Pilar Ramos-Godinez, Luis A. Medina, Luis A. Medina, Patricia Garcia-Lopez   +7 more
doaj   +1 more source

KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment [PDF]

, 2016
Malignant gliomas are among the most frequent and aggressive cerebral tumors, characterized by high proliferative and invasive indexes. Standard therapy for patients, after surgery and radiotherapy, consists of temozolomide (TMZ), a methylating agent ...
Catalano, Myriam, Chece, Giuseppina, D'Alessandro, Giuseppina, Di Angelantonio, Silvia, Esposito, Vincenzo, Esposito, Vincenzo, Grimaldi, Alfonso, Limatola, Cristina, Mainiero, Fabrizio, Porzia, Alessandra, Ragozzino, Davide, Salvati, Maurizio, Santoro, Antonio, Wulff, Heike   +13 more
core   +3 more sources

Temozolomide in aggressive pituitary adenomas and carcinomas

Clinics, 2012
Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas. Temozolomide methylates DNA and, thereby, has antitumor effects.
Leon D. Ortiz, Luis V. Syro, Bernd W. Scheithauer, Fabio Rotondo, Humberto Uribe, Camilo E. Fadul, Eva Horvath, Kalman Kovacs   +7 more
doaj   +1 more source

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma

ESMO Open, 2020
Background Most glioblastoma tumours exhibit intrinsic phosphatidylinositol 3-kinase (PI3K) pathway activation. Preclinical in vitro and in vivo models suggest that buparlisib (an oral pan-PI3K inhibitor) can have an effect on glioblastoma directly and ...
David Mills, Patrick Yung Wen, Jordi A Rodon, Warren Mason, Joseph T Beck, John DeGroot, Valerie Donnet, Mona El-Hashimy, Mark Rosenthal   +8 more
doaj   +1 more source